Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/08/19 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/08/19 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/08/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/08/19 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/08/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
38 |
| 10/03/19 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
57 | |
| 10/03/19 | 8-K | Current report filing |
|
17 | |
| 09/30/19 | EFFECT | Notice of Effectiveness |
|
1 | |
| 09/30/19 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
24 | |
| 09/27/19 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 |
